Staying ahead of the double helix
By Sujatha Byravan,
The Hindu
| 03. 03. 2018
The Delhi High Court recently ruled against discrimination in health insurance by United India Insurance Company involving a person with a heart condition which was perceived to be a genetic disorder. The court held, “Discrimination in health insurance against individuals based on their genetic disposition or genetic heritage, in the absence of appropriate genetic testing and laying down of intelligible differentia, is unconstitutional.”
While the specific features of this case may depend on clauses in the original policy, this is a critical court decision around the broader question of discrimination on the basis of one’s genetic predisposition. As technology for genetic testing and tools to gather family history and compile them in databases become cheaper and more widespread, it becomes imperative that due social and ethical consideration be given to genetic discrimination as the implications are far-reaching and can affect everyone.
Questionable assumptions
Genetic discrimination (GD) is understood to be differential treatment of those not showing symptoms but who are nevertheless treated differently on the basis of any real or assumed genetic characteristics. We must recognise that GD is...
Related Articles
By Editors, Nature | 08.18.2026
Shinya Yamanaka doesn’t see himself as a celebrity. But people do recognize the stem-cell researcher when he’s out for a run, often while training for a marathon, on the streets of Kyoto, Japan.
Many of them call out words of...
By Jenni Fink, Newsweek | 08.19.2026
“Donald Trump” by Gage Skidmore is licensed under CC BY-SA 2.0
President Donald Trump's latest effort to limit birthright citizenship could have consequences for the international surrogacy industry, potentially affecting thousands of intended parents from overseas who travel...
By Ryan Cross, Endpoints News | 08.20.2026
China’s cheap, fast and quiet system for testing cutting-edge medicines is facing scrutiny after the deaths of three people in investigator-initiated trials.
The studies, also known as IITs, allow experimental cell and gene therapies to be tested without oversight from...
By Jessica Hamzelou, MIT Technology Review | 07.30.2026
As of this week in Montana, any biotech company with an experimental drug has a clear path to selling it to consumers. Companies whose drugs have been through preliminary testing—sometimes in as few as 10 healthy people—can pay $12,500 to...